NEJM Clinical Evidence 14-Month Primary Follow-Up Complete

Gene-Edited Allogeneic Islet Transplantation Simulator

Longitudinal immunology trial analyzer modeling the landmark patient report of allogeneic beta-cell engraftment without systemic immunosuppressive therapy.

Stimulated C-Peptide (Day 420)
0.58 nmol/L (1.75 ng/mL)
▲ Up from 0.00 (Undetectable)
Glucose Mgmt Indicator (GMI)
6.0% HbA1c Equivalent
▼ Down from baseline 8.2%
Exogenous Insulin Reduction
60% 22 U/d (was 55 U/d)
No severe hypoglycemia events
CGM Time-In-Range (70-180 mg/dL)
92% 14-day rolling
▲ Target > 70% exceeded
1. Longitudinal Biomarker Trajectory
Interactive Timepoint Scrubbing Day 420 (Month 14)
Day -30 Day 14 Month 1 Month 3 Month 6 Month 9 Month 12 Month 14
Month 14 Assessment (Day 420): Sustained robust stimulated C-peptide secretion with zero systemic immunosuppression (no tacrolimus, cyclosporine, or mycophenolate). Fasting glucose 94 mg/dL, 92% Time-in-Range. Donor-specific anti-HLA antibodies remain undetectable.
2. Cellular Immune-Evasion & Cloaking Engine
Graft Viability: 96%
Engineered β-Islet Cluster
Host CD8+/CD4+ T-Cells
Host Natural Killer (NK) Cells
Macrophages (Inhibited)
HLA-I / B2M Knockout
Eliminates surface MHC Class I to prevent alloreactive CD8+ cytotoxic T-cell engagement.
CD47 "Don't Eat Me"
Overexpressed to bind SIRPα on macrophages and suppress missing-self NK lysis.
CIITA / HLA-II KO
Ablates MHC Class II presentation, neutralizing host helper CD4+ T-cell activation.
Local Cytokine Shield
Membrane-tethered immunomodulators neutralizing local inflammatory TNF-α/IFN-γ.
*Disabling edits simulates acute cellular/humoral allograft rejection cascade.
3. Mixed-Meal Tolerance Test (MMTT) Workbench
Standard 4-hr Liquid Boost Challenge
Physiological Incretion: At Month 12 & 14, plasma C-peptide peaks at 90 minutes post-meal (typical healthy kinetic response), confirming physiological glucose sensing and endogenous insulin release.
4. Modality Comparison Matrix
Translational Landscape
Modality Immunosuppression Supply Scalability 14-Mo Graft Viability Safety Risk Profile
Gene-Edited Allogeneic (Trial) Zero Systemic High (Banked) >95% Intact Minimal off-target; no nephrotoxicity
Standard Cadaveric Islet Tx Lifelong Multi-agent Severely Constrained 60-80% (Variable) Infection, renal impairment, malignancy
Encapsulated Islets (Physical) Zero Systemic Moderate <35% (Fibrosis/Hypoxia) Foreign-body capsule, pericapsular scar
Autologous iPSC-Derived Zero Systemic Low (Patient-specific) Unknown in clinic Autoimmune recurrence, teratoma risk
5. Predictive Cohort Sensitivity Simulator
Adjust trial parameters to predict 14-month retention
Transplanted Graft Mass: 8,500 IEQ/kg
Standard therapeutic dose: 5,000 - 10,000 IEQ/kg
Editing Cleavage Efficiency: 98.4%
Threshold for escape from CD8+ T-cell lysis: >92%
Recipient Autoantibody Titer (GAD65/ZnT8): Low / Normal
0: Low/Quiescent, 1: Moderate, 2: Highly Elevated
Simulated Outcome: High graft persistence predicted (>90% insulin secretory reserve at Month 14).